Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus-Reference-Cited by-同舟云学术

Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus

Published:2017-01-28 Issue:2 Volume:69 Page:376-386
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis & Rheumatology

Author:

Furie Richard¹,Khamashta Munther²,Merrill Joan T.³,Werth Victoria P.⁴,Kalunian Kenneth⁵,Brohawn Philip⁶,Illei Gabor G.⁶,Drappa Jorn⁶,Wang Liangwei⁶,Yoo Stephen⁷,

Affiliation:

1. Hofstra Northwell School of Medicine, Northwell Health; New York New York

2. King's College London and St. Thomas’ Hospital; London UK

3. Oklahoma Medical Research Foundation; Oklahoma City

4. Philadelphia VA Medical Center and University of Pennsylvania; Philadelphia

5. University of California at San Diego School of Medicine; La Jolla California

6. MedImmune; Gaithersburg Maryland

7. Regenxbio; Rockville Maryland

Funder

MedImmune

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/art.39962/fullpdf

Reference32 articles.

1. Targeting interferons in systemic lupus erythematosus: current and future prospects;Mathian;Drugs,2015

2. Mortality in systemic lupus erythematosus;Bernatsky;Arthritis Rheum,2006

3. The economic burden of systemic lupus erythematosus;Panopalis;Best Pract Res Clin Rheumatol,2012

4. Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies;Yurkovich;Arthritis Care Res (Hoboken),2014

5. Long-term outcomes in lupus;Petri;Am J Manag Care,2001

Cited by 599 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Type 1 interferons: A target for immune-mediated inflammatory diseases (IMIDs);Joint Bone Spine;2024-03

2. Vasculitis and vasculopathy associated with inborn errors of immunity: an overview;Frontiers in Pediatrics;2024-01-31

3. Human autoantibodies neutralizing type I IFNs: From 1981 to 2023;Immunological Reviews;2024-01-09

4. The development of litifilimab (BIIB 059) for cutaneous and systemic lupus erythematosus;Immunotherapy;2024-01

5. Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Anti-IFNAR1 Monoclonal Antibody QX006N: A First-in-Human Single Ascending Dose Study in Healthy Chinese Volunteers;BioDrugs;2023-12-27